Equities research analysts at Goldman Sachs Group started coverage on shares of Catalent (NYSE:CTLT) in a report issued on Wednesday, MarketBeat reports. The firm set a “buy” rating and a $50.00 price target on the stock. Goldman Sachs Group’s target price suggests a potential upside of 5.57% from the company’s current price.
Several other research analysts have also issued reports on the stock. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. BidaskClub upgraded shares of Catalent from a “hold” rating to a “buy” rating in a report on Thursday, October 5th. Needham & Company LLC restated a “hold” rating on shares of Catalent in a report on Monday, October 23rd. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “strong-buy” rating and set a $49.00 price objective for the company in a report on Thursday, October 26th. Finally, Piper Jaffray Companies raised their price objective on shares of Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, November 7th. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $45.00.
Shares of Catalent (NYSE CTLT) traded up $0.22 during trading on Wednesday, hitting $47.36. 907,606 shares of the stock were exchanged, compared to its average volume of 799,115. Catalent has a 12 month low of $25.89 and a 12 month high of $47.46. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. The company has a market cap of $6,290.00, a P/E ratio of 55.07, a PEG ratio of 2.97 and a beta of 1.41.
In other Catalent news, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Uwe Roehrhoff bought 7,500 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were bought at an average price of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the business. 361 Capital LLC boosted its position in shares of Catalent by 18.6% during the 3rd quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock valued at $2,795,000 after acquiring an additional 10,974 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Catalent by 25.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock worth $41,773,000 after buying an additional 210,296 shares in the last quarter. Stevens Capital Management LP purchased a new stake in shares of Catalent in the third quarter valued at $2,475,000. Sei Investments Co. grew its position in shares of Catalent by 119.1% in the third quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock valued at $3,761,000 after purchasing an additional 51,212 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Catalent in the second quarter valued at $23,092,000. Institutional investors and hedge funds own 98.88% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.